Grazoprevir

Grazoprevir Market Outlook

The global Grazoprevir market is projected to reach a valuation of approximately USD 2.5 billion by 2035, expanding at a healthy compound annual growth rate (CAGR) of around 8.5% during the forecast period from 2025 to 2035. The growth of this market can be attributed to the rising prevalence of hepatitis C and other liver diseases, alongside increasing awareness regarding the efficient treatment options available. Moreover, advancements in drug formulations that enhance patient compliance and therapeutic outcomes further drive market expansion. The increasing investments in healthcare infrastructure, especially in developing regions, are expected to facilitate greater accessibility and availability of Grazoprevir-based therapies. Additionally, collaborations between pharmaceutical companies and research institutions are enhancing the pipeline of innovative treatment options, contributing to the overall market growth.

Growth Factor of the Market

The Grazoprevir market is significantly driven by the increasing incidence of viral hepatitis, particularly hepatitis C, which is a major public health concern worldwide. As the population ages and risk factors such as intravenous drug use and unprotected sexual encounters become more prevalent, the demand for effective antiviral treatments, including Grazoprevir, is surging. Additionally, the growing awareness and diagnosis rates due to advancements in healthcare services are propelling the market forward. The rising emphasis on developing combination therapies that enhance treatment efficacy and minimize adverse effects contributes to the market's growth trajectory. Furthermore, the government initiatives promoting hepatitis screening and treatment programs are playing a crucial role in increasing the uptake of Grazoprevir, thereby boosting market revenues.

Key Highlights of the Market

• Expected growth in global market size reaching USD 2.5 billion by 2035.
• Projected CAGR of 8.5% from 2025 to 2035.
• Rising prevalence of hepatitis C and liver diseases driving demand.
• Advancements in drug delivery systems enhancing patient compliance.
• Collaborations between pharmaceutical companies and research institutions fueling innovation.

By Product Type

Tablet :

The tablet form of Grazoprevir is one of the most widely utilized product types in the market, primarily due to its ease of administration and patient preference. Tablets offer a convenient dosage form, allowing patients to adhere easily to their prescribed treatment regimens. This form is particularly suitable for long-term treatments, such as those for chronic hepatitis C, where consistent dosing is critical for effective disease management. The tablet form also benefits from established manufacturing processes and distribution channels, making it accessible to a larger population. Furthermore, the ability to incorporate additional compounds into tablet formulations enhances therapeutic efficacy and patient compliance, reinforcing its position within the Grazoprevir market.

Capsule :

Capsules represent another significant product type in the Grazoprevir market, providing a viable alternative to tablet forms. One of the key advantages of capsules is their ability to mask unpleasant tastes, making them more palatable for patients who may be sensitive to flavors or textures. Capsules can also be formulated for delayed or sustained release, allowing for more effective management of drug levels in the bloodstream over time. This characteristic is particularly beneficial in the treatment of chronic conditions, where maintaining optimal drug levels is essential. Moreover, the availability of different capsule sizes enables customization for various patient populations, further enhancing their appeal in the marketplace.

Injection :

Injection forms of Grazoprevir cater to patients who may have difficulty swallowing tablets or capsules, offering a crucial alternative for treatment. This mode of administration is particularly valuable in clinical settings where rapid therapeutic effects are necessary, such as in acute cases of hepatitis C. Injections can provide high bioavailability, ensuring that the medication is delivered effectively into the bloodstream. Furthermore, advances in injection technology, such as pre-filled syringes and auto-injectors, are improving the overall patient experience and adherence to treatment regimens. The increasing trend toward outpatient services and home healthcare is expected to further boost the uptake of injection forms of Grazoprevir.

Suspension :

The suspension form of Grazoprevir is designed primarily for pediatric and elderly patients who may struggle with conventional dosage forms. This liquid formulation allows for easier swallowing and dosage adjustments, ensuring that patients receive the correct amount of medication tailored to their specific needs. Suspensions can also enhance the absorption of the drug, providing a more efficient therapeutic effect. The flexibility in dosing and the ability to mix the suspension with food or beverages make it a favorable choice for a diverse patient population. Additionally, as healthcare providers become increasingly focused on personalized medicine, the demand for suspension formulations is likely to grow.

Solution :

Solutions as a product type in the Grazoprevir market are primarily utilized in hospital settings where intravenous administration is common. This form allows for immediate and effective delivery of the medication, ensuring that patients receive the necessary treatment promptly. Solutions can be particularly advantageous in managing severe cases where rapid therapeutic action is required. Moreover, the development of innovative solution formulations that can be stored at room temperature is enhancing their accessibility and usability in various medical settings. The growing trend towards outpatient and home-based care is expected to drive the adoption of solution formulations as healthcare paradigms shift.

By Application

Hepatitis C :

Hepatitis C remains the primary application for Grazoprevir, significantly influencing the drug's market dynamics. The World Health Organization estimates that over 71 million people globally are living with chronic hepatitis C, necessitating effective antiviral treatments. Grazoprevir, often used in combination therapies, has shown remarkable efficacy in achieving sustained virological response rates, crucial for curing hepatitis C. As screening initiatives increase and the stigma associated with hepatitis C diminishes, more patients are being diagnosed and treated, driving market growth. The ongoing research into the long-term effects of hepatitis C treatments further underscores the importance of Grazoprevir in managing this widespread disease.

Liver Diseases :

The application of Grazoprevir extends beyond hepatitis C, addressing various liver diseases, including liver cirrhosis and fatty liver disease. As these conditions become increasingly prevalent due to rising rates of obesity and lifestyle-related factors, the demand for effective treatments is also on the rise. Grazoprevir's mechanism of action makes it a suitable candidate for therapeutic interventions aimed at improving liver function and preventing disease progression. Furthermore, the growing acknowledgment of the interplay between liver health and overall well-being is enhancing the focus on treatments like Grazoprevir that target liver diseases, thus expanding its application scope and market potential.

HIV :

Though Grazoprevir is not primarily indicated for HIV treatment, its potential in combination therapies is drawing attention within the medical community. Researchers are exploring the synergistic effects of Grazoprevir with antiretroviral drugs to improve treatment outcomes for HIV-positive patients, especially those co-infected with hepatitis C. The unique properties of Grazoprevir may enhance the efficacy of existing HIV treatments, providing a multifaceted approach to managing patients with complex health needs. As the understanding of viral interactions evolves, the exploration of Grazoprevir's application in HIV treatment may unlock significant opportunities for market growth.

Others :

In addition to its primary applications, Grazoprevir is being investigated for various other therapeutic uses in the treatment of viral infections and related complications. Research efforts are focusing on the drug's antiviral properties and its potential effectiveness against other emerging viral infections. The diversification of Grazoprevir's applications may lead to new indications, thereby expanding its market presence and creating new revenue streams. Ongoing clinical trials and studies are critical in establishing the safety and efficacy of Grazoprevir in these additional contexts, ultimately contributing to the overall growth of the market.

By Distribution Channel

Hospital Pharmacies :

Hospital pharmacies play a crucial role in the distribution of Grazoprevir, especially for patients requiring immediate and comprehensive care. As hospitals act as primary treatment centers for patients with severe liver diseases, the availability of Grazoprevir in these settings is essential for timely therapeutic interventions. Hospital pharmacies are equipped to manage complex cases and can provide personalized care through the direct involvement of healthcare professionals. Moreover, the strict regulatory environment surrounding hospital pharmacies ensures that medications are stored, managed, and dispensed in alignment with safety standards, thereby enhancing patient trust in the medication.

Retail Pharmacies :

Retail pharmacies serve as a vital distribution channel for Grazoprevir, providing accessibility to patients outside of hospital settings. With the growing number of patients diagnosed with hepatitis C and other liver diseases, retail pharmacies are increasingly stocking Grazoprevir to meet consumer demand. The convenience of obtaining medications from local retail pharmacies enhances patient adherence to treatment regimens. Additionally, retail pharmacies often provide supplementary services such as medication counseling and monitoring, further supporting patients in their treatment journey. As healthcare becomes more patient-centered, the role of retail pharmacies in the Grazoprevir market is expected to expand significantly.

Online Pharmacies :

The rise of e-commerce has transformed the way patients acquire medications, with online pharmacies becoming an essential distribution channel for Grazoprevir. The convenience of ordering medications from home, combined with the ability to compare prices and access a wider range of products, is appealing to many consumers. Online pharmacies often provide discreet purchasing options, which can be particularly important for patients dealing with sensitive health conditions like hepatitis C. Furthermore, advancements in telemedicine and online consultations are facilitating a more integrated approach to healthcare, allowing patients to receive prescriptions and medications efficiently through digital platforms.

Specialty Clinics :

Specialty clinics that focus on infectious diseases and liver health are essential providers of Grazoprevir, as they offer targeted care and expert management of complex health issues. These clinics typically house healthcare providers with specialized training in handling viral infections and liver diseases, ensuring that patients receive the highest level of care. In these settings, Grazoprevir is often incorporated into comprehensive treatment plans designed to optimize patient outcomes. The collaboration between specialty clinics and pharmaceutical companies facilitates the timely availability of Grazoprevir and enables clinical trials that further enhance the understanding of its efficacy and safety.

By Ingredient Type

Grazoprevir/Ritonavir :

The combination of Grazoprevir and Ritonavir represents a powerful formulation that enhances the antiviral efficacy of Grazoprevir. Ritonavir serves primarily as a booster, increasing the levels of Grazoprevir in the bloodstream and thereby prolonging its action against hepatitis C. This combination therapy has demonstrated significant success in clinical trials, leading to higher cure rates among patients. The growing preference for combination therapies in the treatment of chronic diseases, such as hepatitis C, is anticipated to drive the demand for Grazoprevir/Ritonavir formulations, making them a critical component of the Grazoprevir market.

Grazoprevir/Elbasvir :

The Grazoprevir and Elbasvir combination has emerged as a leading treatment option for hepatitis C, providing a dual-action approach that addresses multiple viral mechanisms. This formulation has shown high efficacy and is often preferred by healthcare providers due to its favorable safety profile. Patients benefit from shorter treatment durations and significantly improved treatment outcomes, making Grazoprevir/Elbasvir a popular choice among clinicians. As awareness of the benefits of combination therapy increases and more patients seek treatment, the market for Grazoprevir/Elbasvir is expected to grow rapidly.

Grazoprevir/Voxilaprevir :

The Grazoprevir/Voxilaprevir combination is particularly beneficial for patients with treatment-refractory hepatitis C. This formulation is designed to target resistant strains of the virus, offering hope to those who have exhausted other treatment options. Clinical studies have demonstrated the effectiveness of this combination in achieving sustained virological response rates in patients with complex medical histories. The growing focus on personalized medicine and precision therapies to address the unique needs of diverse patient populations will likely drive the demand for Grazoprevir/Voxilaprevir combinations in the foreseeable future.

Grazoprevir/Uprifosbuvir :

The combination of Grazoprevir and Uprifosbuvir is another innovative approach to hepatitis C treatment, providing a synergistic effect to enhance antiviral efficacy. This formulation is particularly promising as it targets multiple pathways involved in the viral lifecycle, offering a more comprehensive defense against the virus. The effectiveness of Grazoprevir/Uprifosbuvir in clinical trials has highlighted its potential to improve patient outcomes, positioning it as a valuable player in the Grazoprevir market. The demand for multifaceted treatment regimens that can address the evolving challenges of hepatitis C will continue to support the growth of this combination.

Grazoprevir/NS5A Inhibitor :

Grazoprevir combined with NS5A inhibitors is at the forefront of hepatitis C therapy innovation, leveraging the strengths of both agents to target the virus effectively. NS5A inhibitors have shown remarkable success in enhancing cure rates and reducing the time required for treatment. This combination has become increasingly popular due to its ability to tackle multiple aspects of the hepatitis virus, thereby improving overall treatment outcomes. The ongoing research aimed at optimizing dosage and formulation for this combination therapy is expected to propel its growth in the Grazoprevir market, as healthcare providers seek effective solutions to combat the global hepatitis C epidemic.

By Region

The Grazoprevir market is experiencing varied growth across different regions, reflecting the diverse healthcare landscapes and disease prevalence rates. North America holds a significant share of the market due to the high incidence of hepatitis C and the presence of advanced healthcare infrastructure. The region is expected to maintain its leadership position with a projected CAGR of 8.7% from 2025 to 2035, fueled by increasing awareness, improved diagnostic capabilities, and the availability of innovative treatment options. Additionally, supportive government initiatives aimed at eradicating hepatitis C further bolster the market in North America.

In contrast, the Asia Pacific region is emerging as a key market for Grazoprevir, driven by the rising patient population and improving healthcare access. The growing economies in this region are investing heavily in healthcare infrastructure, which enhances the availability of essential medications like Grazoprevir. According to recent estimates, the Asia Pacific Grazoprevir market is anticipated to grow at a CAGR of 8.2% during the forecast period, supported by increasing healthcare expenditure and rising awareness regarding liver diseases. The demand for Grazoprevir in Europe and Latin America is also on the rise, but the growth rate is comparatively slower, primarily due to regulatory hurdles and varying healthcare policies.

Opportunities

The Grazoprevir market is poised for significant opportunities driven by the increasing global prevalence of hepatitis C and liver diseases. As more individuals become aware of their health conditions and seek treatment, the demand for effective antiviral therapies is expected to rise. Furthermore, the ongoing research and development efforts aimed at improving the formulation and delivery of Grazoprevir provide avenues for expanding its therapeutic applications. Companies that invest in innovative drug delivery systems, such as long-acting formulations or combination therapies, are likely to capture a significant market share. Additionally, emerging markets in Asia and Africa present untapped opportunities, as rising incomes and healthcare investments improve access to necessary treatments.

Another promising opportunity lies in the realm of digital health and telemedicine. The COVID-19 pandemic has accelerated the adoption of telehealth services, enabling patients to access healthcare providers remotely. This trend is expected to continue, providing a platform for educating patients about hepatitis C and promoting treatments like Grazoprevir. Companies that harness digital marketing strategies to reach patients and healthcare providers can enhance their market visibility and drive sales. Partnerships with telehealth platforms and online pharmacies to facilitate seamless access to Grazoprevir can further expand market reach and optimize patient outcomes.

Threats

Despite the promising outlook for the Grazoprevir market, various threats could hinder its growth trajectory. One significant challenge lies in the potential for generic competition, as patents for Grazoprevir formulations begin to expire. The entry of generic alternatives could lead to price erosion, impacting the revenue of companies currently offering branded versions of Grazoprevir. Additionally, the evolving landscape of hepatitis C treatment, characterized by the emergence of new antiviral agents, may pose a threat to the market share of Grazoprevir. As new therapies become available, healthcare providers may opt for alternatives perceived as more effective or with fewer side effects, potentially limiting the uptake of Grazoprevir-based treatments.

Moreover, regulatory challenges remain a concern for the Grazoprevir market. The approval process for new formulations or combinations can be lengthy and complex, delaying market entry and limiting innovation. Additionally, varying regulations across different regions can hinder global market expansion, as companies may struggle to navigate diverse compliance requirements. The ongoing COVID-19 pandemic has also disrupted supply chains and impacted the timely availability of medications, posing further risks to the market. Companies must remain vigilant and adapt to these challenges to sustain their competitive advantage in the Grazoprevir market.

Competitor Outlook

• AbbVie Inc.
• Gilead Sciences, Inc.
• Merck & Co., Inc.
• Bristol-Myers Squibb Company
• Johnson & Johnson
• Takeda Pharmaceutical Company Limited
• Roche Holding AG
• Novartis AG
• Amgen Inc.
• AstraZeneca plc
• Sanofi S.A.
• Pfizer Inc.
• Vertex Pharmaceuticals Incorporated
• Teva Pharmaceutical Industries Ltd.
• Hepion Pharmaceuticals, Inc.

The competitive landscape of the Grazoprevir market is characterized by the presence of several key players who are heavily invested in research and development to deliver innovative treatment options for liver diseases. Companies like AbbVie and Gilead Sciences are leading the charge, continually enhancing their product portfolios and engaging in strategic partnerships to consolidate their market positions. AbbVie, known for its successful Hepatitis C treatments, is particularly focused on expanding access to Grazoprevir in underserved markets while optimizing supply chain efficiencies. Their robust pipeline also indicates ongoing commitment to innovation, which is vital in a rapidly evolving therapeutic landscape.

Gilead Sciences, on the other hand, has been at the forefront of antiviral therapies, leveraging its extensive experience in managing hepatitis C. The company emphasizes the importance of patient-centric solutions and has invested significantly in educational initiatives to raise awareness about hepatitis C treatment options. Their commitment to addressing the needs of diverse patient populations through tailored therapies reinforces their competitive advantage. Furthermore, Gilead's strategic collaborations with healthcare providers and organizations aim to enhance access to Grazoprevir, ensuring consistent distribution channels and patient education.

Merck & Co. is another formidable player in the Grazoprevir market, channeling resources into developing combination therapies that enhance treatment efficacy. Their focus on clinical trials and research endeavors positions them to capitalize on the growing demand for multifaceted treatment regimens. Merck's existing partnerships with healthcare institutions strengthen their position in the market, enabling them to leverage clinical insights and improve their product offerings consistently. Additionally, their robust intellectual property portfolio safeguards their innovations, providing a competitive edge in the marketplace.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 AbbVie Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Novartis AG
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Pfizer Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Sanofi S.A.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 AstraZeneca plc
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Roche Holding AG
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Johnson & Johnson
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Merck & Co., Inc.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Gilead Sciences, Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Bristol-Myers Squibb Company
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Hepion Pharmaceuticals, Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Teva Pharmaceutical Industries Ltd.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Vertex Pharmaceuticals Incorporated
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Takeda Pharmaceutical Company Limited
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Grazoprevir Market, By Application
    • 6.1.1 Hepatitis C
    • 6.1.2 Liver Diseases
    • 6.1.3 HIV
    • 6.1.4 Others
  • 6.2 Grazoprevir Market, By Product Type
    • 6.2.1 Tablet
    • 6.2.2 Capsule
    • 6.2.3 Injection
    • 6.2.4 Suspension
    • 6.2.5 Solution
  • 6.3 Grazoprevir Market, By Ingredient Type
    • 6.3.1 Grazoprevir/Ritonavir
    • 6.3.2 Grazoprevir/Elbasvir
    • 6.3.3 Grazoprevir/Voxilaprevir
    • 6.3.4 Grazoprevir/Uprifosbuvir
    • 6.3.5 Grazoprevir/NS5A Inhibitor
  • 6.4 Grazoprevir Market, By Distribution Channel
    • 6.4.1 Hospital Pharmacies
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies
    • 6.4.4 Specialty Clinics

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Grazoprevir Market by Region
  • 10.3 Asia Pacific - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 India
      • 10.3.1.2 China
      • 10.3.1.3 Japan
      • 10.3.1.4 South Korea
  • 10.4 Latin America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 Brazil
      • 10.4.1.2 Argentina
      • 10.4.1.3 Mexico
  • 10.5 North America - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 USA
      • 10.5.1.2 Canada
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Grazoprevir market is categorized based on

By Product Type

• Tablet
• Capsule
• Injection
• Suspension
• Solution

By Application

• Hepatitis C
• Liver Diseases
• HIV
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Specialty Clinics

By Ingredient Type

• Grazoprevir/Ritonavir
• Grazoprevir/Elbasvir
• Grazoprevir/Voxilaprevir
• Grazoprevir/Uprifosbuvir
• Grazoprevir/NS5A Inhibitor

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• AbbVie Inc.
• Gilead Sciences, Inc.
• Merck & Co., Inc.
• Bristol-Myers Squibb Company
• Johnson & Johnson
• Takeda Pharmaceutical Company Limited
• Roche Holding AG
• Novartis AG
• Amgen Inc.
• AstraZeneca plc
• Sanofi S.A.
• Pfizer Inc.
• Vertex Pharmaceuticals Incorporated
• Teva Pharmaceutical Industries Ltd.
• Hepion Pharmaceuticals, Inc.